Amicus Therapeutics (FOLD) Operating Leases (2019 - 2025)
Historic Operating Leases for Amicus Therapeutics (FOLD) over the last 7 years, with Q3 2025 value amounting to $42.2 million.
- Amicus Therapeutics' Operating Leases fell 954.25% to $42.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.2 million, marking a year-over-year decrease of 954.25%. This contributed to the annual value of $45.1 million for FY2024, which is 2119.37% down from last year.
- According to the latest figures from Q3 2025, Amicus Therapeutics' Operating Leases is $42.2 million, which was down 954.25% from $43.4 million recorded in Q2 2025.
- In the past 5 years, Amicus Therapeutics' Operating Leases registered a high of $60.1 million during Q4 2022, and its lowest value of $42.2 million during Q3 2025.
- In the last 5 years, Amicus Therapeutics' Operating Leases had a median value of $47.8 million in 2024 and averaged $48.8 million.
- Its Operating Leases has fluctuated over the past 5 years, first soared by 1958.16% in 2022, then crashed by 2119.37% in 2024.
- Amicus Therapeutics' Operating Leases (Quarter) stood at $50.8 million in 2021, then increased by 18.43% to $60.1 million in 2022, then fell by 4.87% to $57.2 million in 2023, then dropped by 21.19% to $45.1 million in 2024, then decreased by 6.44% to $42.2 million in 2025.
- Its Operating Leases stands at $42.2 million for Q3 2025, versus $43.4 million for Q2 2025 and $44.2 million for Q1 2025.